Introduction
============

The regression of cutaneous pigmented lesions, benign or malignant, is a well-known phenomenon. The underlying mechanism is not completely understood, but factors like host immune system, UV radiation and trauma have been suggested. Melanoma is a multifactorial disease witch demonstrates a very complex interplay between identifiable risk factors such as UV exposure, phenotype and genotype ([@b1-ol-0-0-9738]--[@b3-ol-0-0-9738]). According to Bastian ([@b4-ol-0-0-9738]) melanoma risk increase with the presence of multiple enlarged acquired nevi. Melanomas can be epithelium-associated or not and can show different age distribution and different relationships to UV exposure.

Melanoma is the tumor with the highest number of reported somatic mutations across human cancer types ([@b5-ol-0-0-9738]). The most common one, that occurs in \~50% of melanomas is BRAF mutation. His variant V600E is the most prevalent one and has been associated with younger age at diagnosis and location of primary tumor often on the trunk. BRAF V600E mutation is also present in 70% of benign nevi ([@b6-ol-0-0-9738]).

After the discovery of BRAF mutations, new targeted therapies like BRAF inhibitors have been introduced for the treatment of melanoma. Although well tolerated when used in clinical practice, they present some adverse events, cutaneous adverse events being the most common ones. Under BRAF therapy dynamic changes in melanocytic lesions like involution of nevi, changes in pigmentation and size and appearance of new melanomas have been described ([@b7-ol-0-0-9738],[@b8-ol-0-0-9738]).

Although partial regression is relatively frequent and occurs in 10--35% of cases, spontaneous complete regression with documented histology is very rare and occurs only in 0.22--0.27% of all melanoma cases ([@b9-ol-0-0-9738]).

Case report
===========

A 58-year-old man presented in the Department of Surgical in 2014 with a 6/4.5 cm subcutaneous tumor on the left lateral chest wall of several months duration. Excision of the lesion revealed a nodular, solid, dermo-hypodermic proliferation with large atypical round, polygonal cells, high number of mitosis (12/10 HPF) at pathological examination. It showed HMB45 and S100 positivity on immunohistochemical staining, concluding to an in-transit metastasis of unknown primary melanoma.

The clinical examination showed in the left lumbar region a suspicious elevated lesion, unknown to the patient, with grayish appearance ([Fig. 1A](#f1-ol-0-0-9738){ref-type="fig"}) and multiple enlarged papillomatous nevi on the trunk ([Fig. 2A](#f2-ol-0-0-9738){ref-type="fig"}). Polarized dermoscopy revealed scar like depigmentation, pigmented globules and white transverse lighter bands between two papillomatous lesions ([Fig. 1B](#f1-ol-0-0-9738){ref-type="fig"}). The clinical and dermoscopic aspect of the lesion, the ipsilateral location indicated a regressed tumor, most likely the primary melanoma. He also presented left-sided axillary lymphadenopathy on clinical examination, confirmed by the CT scan. Surgery was performed on the suspicious lesion and axillary lymph nodes. Pathological examination of the regressed lesion showed flat rete ridges, lamellar fibrosis, increased vascularity, focal lymphocytic infiltrate with rare melanophages and no signs of melanocytic proliferation ([Fig. 1C](#f1-ol-0-0-9738){ref-type="fig"}). Four of the 26 axillary lymph nodes removed showed tumoral cells with positivity for the HMB45 staining concluding to a lymph node melanoma metastasis. After surgery the patient showed rapid progression with detection of pleural metastasis on the CT scan. The patient was diagnosed with a stage IV melanoma with pleural metastasis and a completely regressed primary tumor. BRAF V600E mutation was detected in the subcutaneous lesion.

The patient started Vemurafenib treatment and showed partial response on the pulmonary CT scan after 3 months of therapy, but with numerous cutaneous adverse events: Multiple keratoachantomas, warts and changes in nevi color. One month later an atypical pigmented lesion ([Fig. 3A and B](#f3-ol-0-0-9738){ref-type="fig"}) at the base of a papillomatous nevus that changed from baseline evaluation was excised. It turned out to be a 0.7-mm Breslow index superficial spreading melanoma with less than 1 mitosis/mm^2^, a brisk lymphocytic infiltrate and no regression present ([Fig. 3C](#f3-ol-0-0-9738){ref-type="fig"}). In the same time involution of some papillomatous nevi was observed, by diminished size and lighter color. After other three months Vemurafenib treatment was stopped because of insurance issues and another BRAF inhibitor was started, Dabrafenib, which became available for BRAF mutated melanoma patients in Romania at that time.

After three years of BRAF inhibitor monotherapy all his papillomatous lesions involuted ([Fig. 2B and D](#f2-ol-0-0-9738){ref-type="fig"}). The patient had excellent systemic response with stable disease and no cutaneous or systemic side effects from BRAF inhibitor therapy. He is still under surveillance.

The present case is interesting because the association of completely regressed melanoma with metastases, and development of a new lesion under BRAF treatment.

Methods
=======

We performed a search on PubMed using the terms 'primary melanoma', 'spontaneous regression', 'complete regression' to identify similar cases, restricting the papers to those published in English or French. Additional articles using the reference lists of the identified papers were noted. We found 50 cases of fully regressed melanomas which developed metastasis and three cases of initially confirmed melanomas with complete regression after partial incisional biopsy. Two cases of completely regressed melanomas with no confirmed distant metastasis in spite of extensive work up for two year follow-up were excluded from this study ([@b10-ol-0-0-9738],[@b11-ol-0-0-9738]). Age, sex, location of the tumor and site of metastasis were noted for each case. We also recorded information about the diagnosis of the primary tumor, if it was retrospective or initial and pathologically confirmed. Dermoscopy of complete regressed melanomas was reported only in 10 cases ([@b10-ol-0-0-9738]--[@b12-ol-0-0-9738]).

We did not find in the literature any association between completely regressed melanomas and BRAF mutational status. Demographic and clinical information on the patients are summarized in [Table I](#tI-ol-0-0-9738){ref-type="table"}.

Discussion
==========

Complete regression in melanoma is a rare event, being reported only in 0.22--0.27% of all melanoma cases ([@b9-ol-0-0-9738]). Clinical and pathological presentation of complete regressed melanomas have been extensively described through the literature. Dermoscopic evaluation of completely regressed melanoma is based only on a few case reports in the last 10 years ([@b10-ol-0-0-9738]--[@b12-ol-0-0-9738]). We did not find in the literature any association between completely regressed melanomas and BRAF mutational status. Nevi involution associated with melanoma was reported in the literature as a result of melanoma development followed by spontaneous regression of nevi or as a result of targeted therapy with BRAF inhibitors ([@b35-ol-0-0-9738],[@b36-ol-0-0-9738]).

Clinical presentation of completely regressed melanoma. Completely regressed melanoma usually presents as a hypopigmented macule with pink or scar-like appearance. In rare cases, they can also appear as either hyperpigmented macules, or with remnants of pigmentation as blue-gray discolorations ([@b11-ol-0-0-9738]). Our review showed that all melanomas were epithelium associated ([@b4-ol-0-0-9738]), with a male predominance representing 62.26% of all cases and a median age of 48.5 years. Eighty-three percent of cases presented in relation with low UV exposure in non-chronic sun damaged skin (39,62% involving the trunk and 43.39% involving arms and legs) and only 16.98% were located on chronic sun damaged skin (cervical), in relation with high UV exposure. The diagnosis of regressed melanoma was consistent with criteria of Smith and Stehlin and was retrospective in all cases except one ([@b14-ol-0-0-9738]). Three pathologically confirmed melanomas (two superficial spreading and one nodular melanoma) completely regressed after incisional partial biopsy of primary tumor ([@b32-ol-0-0-9738]--[@b34-ol-0-0-9738]).

Dermoscopic presentation of completely regressed melanoma. There are no established dermoscopic criteria for the diagnosis of complete regressed melanomas. In the literature we found only 10 reported cases of completely regressed melanoma with pathological confirmation and dermoscopic evaluation. Seven cases are reported by Bories *et al* ([@b12-ol-0-0-9738]) who showed that the most frequent dermoscopic features present in all cases were scar-like depigmentation and pink background. Eighty-six percent of patients in his serie had linear irregular vessels as defined by Argenziano *et al* ([@b37-ol-0-0-9738]) and remnants of pigmentation on dermoscopic evaluation. Forty-three percent of patients in Bories *et al* ([@b12-ol-0-0-9738]) serie had 'peppering' as defined by Zalaudek *et al* ([@b38-ol-0-0-9738]), white transverse lighter bands in polarized dermoscopy and globular vessels. High *et al* ([@b11-ol-0-0-9738]) recorded just 'peppering' and dusty blue-gray coloration on dermoscopic evaluation, performed in only two of his 38 melanoma cases reported. Pozzobon *et al* ([@b39-ol-0-0-9738]) found that 'peppering' is a dermoscopic feature frequently associated with regression in BRAF mutated melanoma. They stated that this can be considered a morphological consequence of BRAF mutated melanoma biological behavior.

Our case presented on polarized dermoscopy: Scar-like depigmentation, pigmented globules and white transverse lighter bands, features associated with regression ([Fig. 1B](#f1-ol-0-0-9738){ref-type="fig"}).

Scar-like depigmentation and white transverse lighter bands on a pink background were observed in our patient also at the level of some regressed papillomatous nevi.

Pathological analysis of completely regressed melanoma. To confirm the diagnosis of a completely regressed melanoma is often very difficult. The diagnostic approach is almost always retrospective, with primary lesion being detected in metastatic stage ([@b11-ol-0-0-9738]). There is only one reported case of complete primary regressed melanoma detected before metastatic stage ([@b30-ol-0-0-9738]). According to Massi and LeBoit ([@b40-ol-0-0-9738]) the important issue is to differentiate between a completely regressed nevus and a completely regressed melanoma, and they proposed some criteria. In a regressed nevus the epidermis is normal, with preserved rete ridges, no tumor melanosis and a lymphocytic infiltrate that leaves the nevus undisturbed. In completely regressed melanoma the epidermis is rarely normal; it can be atrophic or irregularly hyperplastic. There is dermal fibrosis, sometimes with foci of tumor melanosis and a rich lymphocytic infiltrate. We can also note the presence of an ectatic superficial vasculature ([Fig. 1C](#f1-ol-0-0-9738){ref-type="fig"}). A challenging situation is when, like in our case, regression involves a melanoma developed in a nevus ([Fig. 1A and B](#f1-ol-0-0-9738){ref-type="fig"}).

Mutational status in completely regressed melanomas. Across human cancer type, melanoma is the tumor with the highest prevalence of somatic mutations ([@b5-ol-0-0-9738]). Bastian ([@b4-ol-0-0-9738]) found that BRAF mutational status was highly present in melanoma arising in non-chronic sun damaged skin, but it can be present in a small percentage in melanomas arising on chronic sun damaged skin or glabrous skin. The most common somatic mutation in melanoma is BRAF V600E, present in up to 90% of BRAF mutated melanomas ([@b41-ol-0-0-9738],[@b42-ol-0-0-9738]). It is associated with younger age at diagnosis and primary lesion located often on the trunk ([@b6-ol-0-0-9738]). Partial regression, found in 10--35% of primary melanoma cases, is a common dermoscopic criteria associated with BRAF mutation ([@b39-ol-0-0-9738]). We present for the first time to our knowledge a case of completely regressed primary melanoma which harbors BRAF V600E mutation in the metastatic lesion and develops a second primary BRAF wild-type melanoma under BRAF inhibitors.

BRAF mutation is present in nevi in a higher percentage than in melanoma (70--82% in nevi vs. 50--60% in melanomas) ([@b43-ol-0-0-9738]). The introduction of BRAF inhibitor therapy in the treatment of melanoma improved response rates and overall survival in patients with melanoma but with nevi dynamic change as a common side effect. Nevi involution, especially for the papillomatous compound type, increasing in size and pigmentation for the flat lesions but also appearance of new BRAF wild-type melanoma were reported ([@b36-ol-0-0-9738],[@b44-ol-0-0-9738]). This is due to paradoxical activation of MAPK pathway, especially with BRAF inhibitor monotherapy, also associated with resistance to therapy ([@b45-ol-0-0-9738]).

Spontaneous complete regression - possible mechanisms. A lot of factors leading to complete regression in melanoma were mentioned in the literature. There are exogenous factors like surgical trauma, vaccines (BCG, rabies), UV exposure, medication (BRAF inhibitors) and endogenous factors like pregnancy ([@b32-ol-0-0-9738],[@b33-ol-0-0-9738],[@b46-ol-0-0-9738]--[@b49-ol-0-0-9738]). The host immune system has an important role in tumor regression in melanoma. The occurrence of regression in primary tumor after lymph node or visceral metastases is highly related to an effective immune response against tumor cells ([@b46-ol-0-0-9738],[@b49-ol-0-0-9738]).

In conclusion, we present for the first time to our knowledge a case of completely regressed BRAF V600E mutated melanoma which showed nevi involution and developed a new BRAF wild-type melanoma after therapy with BRAF inhibitors. On one hand, this case favors the role of BRAF mutation in melanoma immune pathogenesis, and on the other hand, shows the importance of clinical and dermoscopic follow-up in melanoma patients. Our review shows that the diagnosis of completely regressed melanoma is very difficult, especially because there are no unifying concepts in assessing complete regression dermoscopically and pathologically.
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![Clinical, dermoscopic and pathological presentation of a completely regressed melanoma. (A) Clinical presentation of the regressed melanoma showing a suspicious elevated lesion with grayish appearance. (B) Polarized dermoscopy of the regressed melanoma showing scar like depigmentation, pigmented globules and white transverse lighter bands. (C) Histologic analysis of the regressed melanoma showing flat rete ridges, lamellar fibrosis, increased vascularity, focal lymphocytic infiltrate with no melanocytic proliferation. Hematoxylin and eosin; magnification, ×50.](ol-17-05-4176-g00){#f1-ol-0-0-9738}

![Clinical image of the patient before and after three years of BRAF therapy. (A) Baseline clinical evaluation of the back and (C) front before treatment. (B) Clinical evaluation of the back and (D) front after three years of BRAF inhibitors.](ol-17-05-4176-g01){#f2-ol-0-0-9738}

![Clinical, dermoscopic and pathological presentation of the second melanoma under BRAF therapy. (A) Clinical presentation showing an atypical pigmented lesion at the base of a nonpigmented papillomatous nevus. (B) Polarized dermoscopy of the new melanoma showing flat eccentric pigmentation at the base of a nonpigmented papillomatous nevus. (C) Histologic presentation of the new melanoma showing nests of melanocites with variable size and shape, pagetoid spreading, large cells with abundant eosinophilic cytoplasm with prominent nuclei. Hematoxylin and eosin; magnification, ×100.](ol-17-05-4176-g02){#f3-ol-0-0-9738}

###### 

Demographic and clinical information on the patients.

  Author (year)                                                  Ref.                   No. of patients   Age (years)   Sex   Location of primary tumor   Sites of metastasis                                      Diagnosis of primary tumor
  -------------------------------------------------------------- ---------------------- ----------------- ------------- ----- --------------------------- -------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------
  Dasgupta *et al*, 1963                                         ([@b13-ol-0-0-9738])   2                 35            M     Trunk                       Ipsilateral cervical and axillary lymph nodes            Retrospective/skin examination/excisional biopsy
                                                                                                          49            M     Trunk                       Ipsilateral axillary lymph nodes                         Retrospective/skin examination/excisional biopsy
  Smith *et al*, 1965                                            ([@b14-ol-0-0-9738])   7                 40            M     Trunk                       Ipsilateral axillary                                     Retrospective/skin examination/excisional biopsy
                                                                                                          45            M     Leg                         Ipsilateral inguinal lymph nodes                         Retrospective/skin examination/excisional biopsy
                                                                                                          29            F     Arm                         Ipsilateral epitrochlear & axillary lymph nodes          Retrospective/skin examination/excisional biopsy
                                                                                                          27            M     Arm                         Ipsilateral axillary lymph nodes                         Retrospective/skin examination/excisional biopsy
                                                                                                          33            M     Cervical                    Ipsilateral cervical lymph nodes                         Retrospective/skin examination/excisional biopsy
                                                                                                          31            F     Leg                         Ipsilateral inguinal lymph nodes                         Retrospective/skin examination/excisional biopsy
                                                                                                          44            M     Trunk                       Ipsilateral axillary lymph nodes                         Retrospective/skin examination/excisional biopsy
  Todd *et al*, 1966                                             ([@b15-ol-0-0-9738])   1                 31            M     Cervical                    Ipsilateral cervical lymph nodes                         Retrospective/skin examination/excisional biopsy
  Milton *et al*, 1967                                           ([@b16-ol-0-0-9738])   1                 53            M     Cervical                    Contralateral cervical lymph nodes                       Retrospective/skin examination/excisional biopsy
  Cochran *et al*, 1970                                          ([@b17-ol-0-0-9738])   2                 41            M     Leg                         Ipsilateral inguinal lymph nodes                         Retrospective/skin examination/excisional biopsy
                                                                                                          50            M     Leg                         Ipsilateral inguinal lymph nodes                         Retrospective/skin examination/excisional biopsy
  McGovern, 1975                                                 ([@b18-ol-0-0-9738])   1                 57            M     Trunk                       Supraclavicular and. cervical lymph nodes                Retrospective/skin examination/excisional biopsy
  McDougal *et al*, 1976                                         ([@b19-ol-0-0-9738])   1                 72            F     Cervical                    Ipsilateral cervical lymph nodes                         Retrospective/skin examination/excisional biopsy
  Whicker *et al*, 1980                                          ([@b20-ol-0-0-9738])   1                 53            F     Cervical                    Ipsilateral cervical lymph nodes                         Retrospective/skin examination/excisional biopsy
  Pelligrini, 1980                                               ([@b21-ol-0-0-9738])   1                 50            F     Leg                         Ipsilateral inguinal lymph nodes                         Retrospective/skin examination/excisional biopsy
  Landthaler and Braun-Falco, 1981                               ([@b22-ol-0-0-9738])   2                 41            M     Leg                         Ipsilateral inguinal lymph nodes                         Retrospective/skin examination/excisional biopsy
                                                                                                          63            F     Leg                         Ipsilateral inguinal lymph nodes                         Retrospective/skin examination/excisional biopsy
  Kessler *et al*, 1984                                          ([@b23-ol-0-0-9738])   1                 40            F     Leg                         Ipsilateral inguinal lymph nodes                         Retrospective/skin examination/excisional biopsy
  Rampen and Meijer, 1985                                        ([@b24-ol-0-0-9738])   1                 37            M     Cervical                    Brain                                                    Retrospective/skin examination/excisional biopsy
  Paul and Müllhofer, 1990                                       ([@b25-ol-0-0-9738])   1                 60            M     Trunk                       Ipsilateral inguinal lymph nodes                         Retrospective/skin examination/excisional biopsy
  Bottger *et al*, 1992                                          ([@b26-ol-0-0-9738])   2                 41            M     Leg                         Ipsilateral inguinal lymph nodes                         Retrospective/skin examination/excisional biopsy
                                                                                                          63            F     Leg                         Ipsilateral inguinal lymph nodes                         Retrospective/skin examination/excisional biopsy
  Avril *et al*, 1992                                            ([@b27-ol-0-0-9738])   7                 40            F     Leg                         Ipsilateral inguinal lymph nodes                         Retrospective/skin examination/excisional biopsy
                                                                                                          57            M     Trunk                       Contralateral inguinal lymph nodes                       Retrospective/skin examination/excisional biopsy
                                                                                                          42            M     Trunk                       Ipsilateral axillary lymph nodes                         Retrospective/skin examination/excisional biopsy
                                                                                                          68            M     Arm                         Ipsilateral axillary lymph nodes                         Retrospective/skin examination/excisional biopsy
                                                                                                          52            M     Arm                         Ipsilateral axillary lymph nodes                         Retrospective/skin examination/excisional biopsy
                                                                                                          33            F     Trunk                       Ipsilateral axillary lymph nodes                         Retrospective/skin examination/excisional biopsy
                                                                                                          63            M     Trunk                       Ipsilateral axillary lymph nodes                         Retrospective/skin examination/excisional biopsy
  Shai *et al*, 1994                                             ([@b9-ol-0-0-9738])    1                 53            F     Leg                         Ipsilateral inguinal lymph nodes                         Retrospective/skin examination/excisional biopsy
  Sais *et al*, 1994                                             ([@b28-ol-0-0-9738])   1                 57            F     Cervical                    Ipsilateral parotid gland, brain                         Retrospective/skin examination/excisional biopsy
  High *et al*, 2005                                             ([@b11-ol-0-0-9738])   4                 68            M     Trunk                       Ipsilateral axillary lymph nodes, brain                  Retrospective/skin examination/excisional biopsy
                                                                                                          48            M     Trunk                       Ipsilateral axillary lymph nodes                         Retrospective/skin examination/excisional biopsy
                                                                                                          55            M     Leg                         Ipsilateral inguinal lymph nodes                         Retrospective/skin examination/excisional biopsy
                                                                                                          21            F     Leg                         Ipsilateral inguinal lymph nodes                         Retrospective/skin examination/excisional biopsy
  Emanuel *et al*, 2008                                          ([@b29-ol-0-0-9738])   2                 40            F     Trunk                       Regional lymph nodes NOS                                 skin examination/excisional biopsy first
                                                                                                          53            M     Cervical                    Soft tissue NOS                                          Retrospective/skin examination/excisional biopsy
  Bories *et al*, 2008                                           ([@b12-ol-0-0-9738])   1                 63            M     Trunk                       Bilateral axillary lymph nodes                           Retrospective/skin examination/Excisional biopsy
                                                                                        2                 38            F     Trunk                       Ipsilateral sus-clavicular lymph nodes                   Retrospective/skin examination/Excisional biopsy
                                                                                        3                 48            M     Foot                        Ipsilateral inguinal lymph nodes and lung                Retrospective/skin examination/Excisional biopsy
                                                                                        4                 36            F     Cervical                    Ipsilateral cervical lymph nodes                         Retrospective/skin examination/Excisional biopsy
                                                                                        5                 63            M     Trunk                       Ipsilateral axillary lymph nodes                         Retrospective/skin examination/Excisional biopsy
                                                                                        6                 68            F     Leg                         Ipsilateral inguinal lymph nodes, iliac nodes and bone   Retrospective/skin examination/Excisional biopsy
                                                                                        7                 78            F     Leg                         Ipsilateral inguinal lymph nodes                         Retrospective/skin examination/Excisional biopsy
  Margaritescu *et al*, 2014                                     ([@b30-ol-0-0-9738])   3                 45            F     Trunk                       Ipsilateral axillary lymph nodes                         Retrospective/skin examination/excisional biopsy
                                                                                                          45            M     Trunk                       Ipsilateral axillary lymph nodes                         skin examination/Biopsy first
                                                                                                          40            M     Trunk                       Brain Ipsilateral axillary lymph nodes                   Retrospective/skin examination/excisional biopsy
  Yamada *et al*, 2016                                           ([@b31-ol-0-0-9738])   1                 65            M     Leg                         Ipsilateral inguinal lymph nodes                         Retrospective/skin examination/excisional biopsy
  Complete regression of primary tumor after incisional biopsy                                                                                                                                                     
  Dunn *et al*, 2008                                             ([@b32-ol-0-0-9738])   1                 39            F     Trunk                       No distant metastasis                                    Initial partial biopsy (SSM 1.8 mm growth Breslow thickness, vertical fase) complete regression in 12 weeks (excision)
  Menzies and McCarthy, 2015                                     ([@b33-ol-0-0-9738])   1                 62            M     Leg                                                                                  Initial partial biopsy (SSM 0.7 mm Breslow thickness) complete regression in 18 months on punch biopsy
  Khosravi *et al*, 2016                                         ([@b34-ol-0-0-9738])   1                 49            M     Trunk                       Multiple metastasis                                      Initial partial biopsy (ulcerated NM 8 mm Breslow thickness) complete regression in 4 weeks (excision)
